// App-Quantinova.ai

: TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES

Researchers

Presenter

  • Stephan Grupp

Principal Investigators

  • Andre Baruchel

  • Theodore W. Laetsch

  • Timothy Driscoll

  • Muna Qayed

  • John Levine

  • Michael Boyer

  • Joerg Krueger

  • Gary Douglas Myers

  • Christina Peters

  • Susana Rives

  • Peter Bader

  • Nicolas Boissel

  • Stella Davies

  • Kara Davis

  • Eneida Nemecek

  • Gregory Yanik

  • Ranjan Tiwari

  • Srivani Konduri

  • Lamis Eldjerou

  • Andrea Chassot Agostinho

  • Stephen Hunger

  • Michael Pulsipher

Medical Centers

  • The Childrenaaas Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

  • Universite Paris Diderot et Institut Universitaire d'Hematologie,Paris,France

  • University of Texas Southwestern, Dallas, TX, United States

  • Duke University, Duham, United States

  • Emory University, Atlanta, Georgia, United States

  • The Mount Sinai School of Medicine, New York, United States

  • University of Utah, Salt Lake City, Utah, United States

  • Hospital for Sick Children, Toronto, ON, Canada

  • BMT, CHildrens Mercy Hospital, Kansas City, MO, United States

  • St. Anna Children s Hospital, Vienna, Austria

  • Sant Pau Hospital, Barcelona, Spain

  • University Childrens Hospital , Frankfurt,

  • Hopital Saint-Louis/Universite, Paris, France

  • Cincinnati Childrens Hospital, Cincinnati, Ohio, United States

  • Stanford University Medical Center, Stanford, California, United States

  • Oregon Health and Science University, Portland, Oregon, United States

  • The University of Michigan, Ann Arbor, Michigan, United States

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • Children's Hosp Los Angeles, Los Angeles, CA, United States.

Locations

  • United States

  • France

  • Canada

  • Austria

  • Spain

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • tisagenlecleucel-t

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02435849

  • NCT02228096

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved